Zura Bio Limited (NASDAQ:ZURA) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC grew its position in shares of Zura Bio Limited (NASDAQ:ZURA) by 51.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,005 shares of the company’s stock after purchasing an additional 7,828 shares during the period. SG Americas Securities LLC’s holdings in Zura Bio were worth $58,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Braidwell LP acquired a new position in Zura Bio during the third quarter worth $10,040,000. Geode Capital Management LLC lifted its stake in Zura Bio by 70.6% during the third quarter. Geode Capital Management LLC now owns 912,625 shares of the company’s stock worth $3,706,000 after purchasing an additional 377,545 shares in the last quarter. Sphera Funds Management LTD. acquired a new position in Zura Bio during the third quarter worth $2,999,000. State Street Corp lifted its stake in Zura Bio by 47.5% during the third quarter. State Street Corp now owns 395,059 shares of the company’s stock worth $1,604,000 after purchasing an additional 127,300 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Zura Bio by 51.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 291,807 shares of the company’s stock worth $1,185,000 after purchasing an additional 98,972 shares in the last quarter. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Chardan Capital decreased their price target on Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Leerink Partnrs upgraded Zura Bio to a “strong-buy” rating in a research note on Monday, November 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a research report on Wednesday, December 11th. HC Wainwright reaffirmed a “neutral” rating and set a $5.00 price objective on shares of Zura Bio in a research report on Tuesday, December 24th. Finally, Leerink Partners started coverage on Zura Bio in a research report on Monday, November 4th. They set an “outperform” rating and a $15.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $15.80.

Zura Bio Price Performance

NASDAQ:ZURA opened at $1.50 on Friday. The business’s fifty day moving average price is $2.09 and its 200 day moving average price is $3.24. Zura Bio Limited has a 12 month low of $1.35 and a 12 month high of $6.35.

Insider Activity at Zura Bio

In related news, Director Parvinder Thiara sold 1,001,633 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $2.73, for a total value of $2,734,458.09. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 22.10% of the stock is currently owned by corporate insiders.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.